Harvard Bioscience Inc. (NASDAQ:HBIO) shares rose 3.1% on Tuesday . The stock traded as high as $2.72 and last traded at $2.70, with a volume of 68,348 shares. The stock had previously closed at $2.62.

Separately, Zacks Investment Research upgraded shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th.

The firm’s market cap is $92.65 million. The company’s 50 day moving average is $2.82 and its 200-day moving average is $2.98.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.03 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.03. The business earned $26.10 million during the quarter, compared to the consensus estimate of $26.60 million. Equities research analysts predict that Harvard Bioscience Inc. will post $0.16 EPS for the current fiscal year.

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.